F. Hoffmann-La Roche Ltd. v. Empagran S. A.
The Court ruled that foreign buyers who were injured only in foreign markets by a price-fixing scheme cannot sue under U.S. antitrust law, even though other buyers were separately harmed inside the United States by the same conduct.
The decision limits how far American antitrust law reaches into anticompetitive conduct occurring largely overseas, respecting other countries' authority to regulate harm suffered by their own consumers.
“Why should American law supplant, for example, Canada's or Great Britain's or Japan's own determination about how best to protect Canadian or British or Japanese customers from anticompetitive conduct engaged in significant part by Canadian or British or Japanese or other foreign companies?”
The Court explains why U.S. antitrust law should not override other nations' choices about protecting their own consumers.
How it got here: A federal trial court dismissed the foreign purchasers' claims; the D.C. Circuit reversed; the Supreme Court took the case to resolve a circuit split over the statute.
The Case in Depth
What happened
Foreign and domestic vitamin purchasers sued vitamin manufacturers and distributors, alleging a worldwide price-fixing conspiracy that raised prices both in the United States and in foreign countries including Ukraine, Australia, Ecuador, and Panama. The foreign purchasers had bought vitamins entirely outside U.S. commerce, for delivery abroad, and their claims about foreign price increases were independent of the harm suffered by U.S. buyers.
The question before the Court
If vitamin makers around the world fixed prices, raising costs in the U.S. and separately in places like Ecuador, could a foreign buyer who was only hurt abroad sue under American antitrust law?
The Court's answer
No — a foreign purchaser hurt only by higher prices in a foreign market cannot use the Sherman Act to sue, even if the same price-fixing scheme also caused separate, independent harm to buyers inside the United States. The Foreign Trade Antitrust Improvements Act generally excludes foreign anticompetitive conduct from U.S. antitrust law, and the exception that restores coverage when conduct harms U.S. commerce does not stretch to cover foreign harm that has nothing to do with that domestic effect.
The Court reasoned that letting foreign plaintiffs sue in U.S. courts over purely foreign injury would needlessly interfere with other countries' authority to decide how to police and remedy harm to their own consumers, and found no history of American courts ever applying the Sherman Act this way before the statute existed. The case was sent back so the lower court can consider a separate argument that the foreign and domestic harms were actually connected.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Foreign purchasers hurt by a global cartel can no longer piggyback on U.S. antitrust law and its generous treble-damages remedy just because the same cartel also hurt American buyers. Companies operating internationally get more certainty that U.S. courts won't become a forum for lawsuits over harm that happened entirely abroad, and other nations retain control over remedies for their own consumers.
What changes now
The case goes back to the Court of Appeals, which must now consider the foreign purchasers' separate argument that their foreign injury was not actually independent of the domestic price effects — because keeping the cartel together required the higher U.S. prices too. If that argument succeeds, the foreign buyers' claims could still proceed; if not, their claims are barred.
What this does not decide
The Court did not decide whether foreign injury is barred when it is causally linked to, rather than independent of, the domestic price effects — the foreign purchasers' "but for" argument that the domestic and foreign harms were connected was left for the Court of Appeals to consider on remand.
Concurrences and dissents
Concurrence — Justice Scalia
Justice Scalia agreed with the outcome but wrote separately to state a narrower rationale: the statute's language is readily susceptible to the Court's reading, and that reading is the only one consistent with the traditional practice of deferring to how foreign countries apply their own laws within their own territory.
How the Court got there
The legal reasoning, step by step
- The Court read the Foreign Trade Antitrust Improvements Act (FTAIA) as generally removing foreign anticompetitive conduct from the Sherman Act's reach, then asked whether an exception restored coverage because the conduct also caused a direct, substantial, and foreseeable domestic effect that itself gave rise to a claim.
- The Court applied a longstanding rule that ambiguous statutes should be read to avoid unreasonable interference with other countries' sovereign authority over their own commerce, a principle rooted in customary international law that Congress is presumed to respect.
- Applying that principle, the Court found it reasonable for U.S. antitrust law to redress harm caused inside the United States, but found no comparable justification for using U.S. law to redress foreign harm that occurred independently of any domestic injury, since doing so would let American courts second-guess how other nations choose to remedy harm to their own citizens.
- The Court also found nothing in the FTAIA's text or history suggesting Congress meant to expand, rather than limit, the Sherman Act's reach into wholly foreign harm, and noted that no court before 1982 had applied the Sherman Act to redress purely independent foreign injury.
- Weighing both the comity concern and the lack of historical support together, the Court concluded that the domestic-effect exception does not cover a claim resting solely on foreign injury that is independent of any domestic harm the conduct caused.
Doctrinal impact
Cases affected by this decision
Distinguishes Timken Roller Bearing Co. v. United States (341 U. S. 593)
Distinguished because the government, not a private plaintiff, sought relief for both foreign and domestic cartel harm.
Distinguishes United States v. National Lead Co. (332 U. S. 319)
Distinguished as a government antitrust suit, unlike the private foreign-injury claim at issue here.